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MALIGNANCY
John Joseph Wysolmerski
1986
Hypercalcemia is the most common paraneoplastic syndrome. There are
two pathophysiologic groups of patients manifesting malignancy associated
hypercalcemia. One group suffers from tumors that metastasize to the skeleton
and cause Local Osteolytic Hypercalcemia. The other group suffers from tumors
that lack skeletal involvement and cause Humoral Hypercalcemia of Malignancy.
A PTH-like, adenylate cyclase-stimulating factor(s) has been implicated as the
causative agent in Humoral Hypercalcemia of Malignancy. As part of the effort to
isolate and purify this factor, studies were undertaken to define some of its
physical characteristics. It was found that, like bPTH(1-34), this adenylate
cyclase-stimulating factorfs) is not sensitive to severe reducing conditions.
Also similar to PTH, the factor(s) was found to be sensitive to oxidation by
hydrogen peroxide. However, it is oxidized much more gradually than is bPTH(134). It was found that the factor(s) does not irreversibly lose its bioactivity
when exposed to pH's ranging from 3 to 10. Finally, initial attempts to generate
an active peptide fragment by partial digestion with cyanogen bromide and initial
attempts to ascertain whether the factor(s) is a glycoprotein, using lectin
affinity columns, are described.
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Figure 1
Standard dose-response curves generated by bPTH and ACSF.

Figure 2
a - Dose-response curves generated by bPTH(1 -34) exposed to
reducing conditions.
b - Dose-response curves generated by ACSF exposed to
reducing conditions.

FIGURE 3
a - Dose-response curves generated by bPTH(1-34) exposed to
hydrogen peroxide for varying lengths of time.
b - Dose-response curves generated by ACSF exposed to
hydrogen peroxide for varying lengths of time.
c - Loss of bioactivity of bPTH(1-34) and ACSF with increasing
duration of oxidation.

FIGURE 4
Dose-response curves generated by ACSF after having been
sequentially oxidized and then reduced.

FIGURES
a - Effects of ammonium acetate adjusted to various pH's on
the renal adenylate cyclase assay.
b - Profile of bioactivity of bPTH(1-34) and ACSF exposed to
various pH's, assayed in ammonium acetate.
c - Profile of bioactivity of bPTH(1-34) and ACSF exposed to
various pH's, ammonium acetate lyophilized prior to assay.

FIGURE 6
a - Concanavalin-A positive control: 125l

B-

HCG elution profile,

b - ACSF bioactivity recovered from Concanavalin-A column,
c - ACSF bioactivity recovered from Wheat Germ Lectin column.
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In 1921 Kramer and Tisdall introduced a chemical method for the direct
measurement of serum calcium (1). With the modifications of Clark and Collip
(2) this test became routinely available for use in both clinical medicine and
research.

Not very long after the advent of this technology, Zondek et. aL (3)

recorded the first observations of hypercalcemia in a patient with malignancy.
Since this report, much attention has been given to malignancy - associated
hypercalcemia (MAHC). Today it is recognized to be the most common
paraneoplastic complication.
Ten to twenty percent of all cancer patients (4) and fifteen to forty
percent of patients with selected neoplasms (5) develop hypercalcemia at some
point in their disease. This makes MAHC the second most common cause of
hypercalcemia in the general population; primary hyperparathyroidism is the
most common cause.

Since the latter is often an asymptomatic, ambulatory

disease (6,7), and since cancer patients are more frequently hospitalized, MAHC
becomes the most common cause of hypercalcemia among inpatients (8,9).
Mundy, Cove, and Fisken have looked at the overall incidence of MAHC most
closely (6).

They studied 207 patients presenting with hypercalcemia in

Birmingham, England, a community of approximately one million people. MAHC
accounted for thirty-five percent of all hypercalcemia patients in this
population, an incidence rate of 150 new patients per million population per year
(6,9).
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Although hypercalcemia is a frequent companion of malignancy, it is not a
ubiquitous one. That is to say, it seems to be associated with only certain types
of cancer.

For example, hypercalcemia rarely accompanies gastrointestinal

cancers (9), and although associated with squamous lung cancer, it is rarely
associated with either adenocarcinoma or small cell carcinoma of the lung (10).
The syndrome has been repeatedly shown to occur almost exclusively with a
specific subset of malignancies (8 -15). These are: breast carcinoma, multiple
myeloma, squamous tumors of lung, esophagus, head and neck, skin, cervix, and
vulva, renal cell carcinoma, urothelial carcinomas, malignant lymphomas
including Burkit's lymphoma, ovarian carcinoma, and lymphosarcomas. This set
of neoplasms can be classified further based on the presence or absence of
skeletal metastases. Mundy and Martin (9) use these two critera, histology and
metastatic involvement, to define 3 groups of tumors associated with
hypercalcemia:

solid tumors without skeletal metastases, solid tumors with

skeletal metastases, and hematologic malignancies. Stewart et. aL (8) combine
the hematologic malignancies with the solid tumors and simply consider two
groups: those tumors associated with skeletal metastases and those tumors
with limited or no skeletal metastases.

Looking at the tumors either way, it is

clear (10-15) that breast cancer, multiple myeloma and lymphomas are the
tumors that cause hypercalcemia in the presence of skeletal metastases. The
squamous, renal, urothelial and ovarian tumors are those that cause
hypercalcemia in the absence of skeletal involvement.
These distinctions have implications for pathogenesis. Neoplasms that
require an extensive skeletal tumor burden to cause hypercalcemia most likely
exert their hypercalcemic effects locally, within and around metastatic lesions
in bone.

On the other hand, the fact that some neoplasms can cause

-
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hypercalcemia without a skeletal tumor burden suggests that they may exert
their hypercalcemic effects over a distance, perhaps via a humoral mechanism.
Both of these general mechanisms will be discussed below.

However, it is

necessary first to consider their common endpoint, increased bone resorption.
In both types of MAHC, with or without bony metastases, excess calcium
comes from the skeleton (8,9).

Normal calcium homeostasis relies on the

balance struck between the gut absorption, the skeletal turnover, and the renal
excretion of the ion (5,6,16).

Several lines of evidence have established that

increased skeletal bone resorption and neither gut hyperabsorption nor decreased
renal clearance of calcium accounts for the hypercalcemia associated with
neoplastic disease.

First, in a study of fifty unselected patients with MAHC,

Stewart et al. found mean plasma 1,25 dihydroxy-vitamin D (1,25 (OH)2 Vit. D)
values to be markedly depressed in both patients with bony metastases and in
patients without bony metastases (14). Since 1,25 (OH)2 Vit. D is the major
factor mediating intestinal absorption of calcium (5,17) and since calcium is
malabsorbed in its absence (5,18), it is, therefore, improbable that calcium
hyperabsorption is the cause of MAHC.
observations

that dietary

calcium

Further evidence comes from the

restriction

does

not

mitigate the

hypercalcemia in either humans with MAHC (19,20) or in animal models of MAHC
(21.22).

Finally, Coombes £i. al (15), using

radioactive calcium intestinal

absorption techniques directly showed that both groups of patients with MAHC
had depressed levels of intestinal calcium absorption. Hence, the excess calcium
in MAHC does not come from the diet.
The evidence against decreased renal excretion of calcium is equally
compelling. In fact, Stewart £i. al (14) found just the opposite; fasting urinary
calcium excretion was increased in patients with MAHC. It was higher in these
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patients than in either normocalcemic cancer patients or patients with primary
hyperparathyroidism.

Similar observations have been noted repeatedly

(10,13,15,23,24). For a given filtered load, the nephron, rather than holding on to
calcium, excretes greater amounts.

This is true whether one measures

fractional calcium excretion or twenty-four hour urine calcium excretion.
The lack of calcium hyperabsorption by the intestine or excessive
reabsorption by the nephron is indirect evidence that the hypercalcemia
associated with cancer is a result of stepped-up bone resorption. There is also
direct evidence.

Several studies of bone histology and quantitative bone

histomorphometry have demonstrated enhanced bone destruction and increased
bone resorption in MAHC with or without local metastases (25-28). Studies of
calcium kinetics in hypercalcemic cancer patients (15,19) have also indicated an
increase in bone resorption. In fact, one careful study of a patient with multiple
myeloma (19) was able to document a parallel relationship between increased
serum calcium concentrations and increased bone resorption. Finally, calcitonin
(29) and mithramycin (30) are two drugs which have been shown to be
efficacious in treating MAFIC. Since each of these agents inhibits bone resorption
and since each does so through a separate and distinct mechanism, their dual
efficacy is strong supporting evidence that increased bone resorption is the
cornerstone of MAHC.

LOCAL OSTEOLYTIC HYPERCALCEMIA
One of the two major pathophysiologic groups of cancers associated with
hypercalcemia consists of those tumors with extensive skeletal metastases.
These tumors seem to cause hypercalcemia through the local osteolytic effects
of the metastatic lesions (8,9). Therefore, this subset of MAHC is referred to as

5

Local Osteolytic Hypercalcemia or LOH (8). Neoplasms included in this group are
a common source of MAHC, accounting for anywhere from twenty to ninety
percent of all cases, depending on the study (13,14). Histologically they include
solid tumors, which are almost exclusively breast carcinomas, and hematologic
cancers, most often

multiple myeloma and less commonly lymphomas and

lymphosarcomas (8,9,14). Despite their common occurrence, the mechanisms
responsible for hypercalcemia in these neoplasms are less well defined than the
mechanisms at play in the second major group, tumors without bone metastases.
Gutman el. e[.(11) published the first large series of patients with MAHC. Most of
these patients had either breast cancer or multiple myeloma and they all had
extensive skeletal tumor burdens. They were patients displaying LOH. Because
of this universal skeletal involvement, the authors concluded that the
hypercalcemia was

caused by direct destruction of bone by the enlarging

metastatic lesions.

Since this report, it has been recognized that in both

hematologic tumors (31) and in solid tumors(32) there is some correlation
between the extent of skeletal tumor involvement and the presence of
hypercalcemia.

For example, it has been observed that patients with breast

cancer and certain types of lung cancer usually develop hypercalcemia only late
in their disease, after they have extensive osteolytic bone destruction (32).
However, it has also become increasingly clear that any correlation between
skeletal metastases and hypercalcemia is, at best, a rough one. First, not all
tumors that metastasize to bone cause hypercalcemia. For instance, small cell
carcinoma is the lung cancer most frequently associated with bone metastases,
yet it rarely causes hypercalcemia (10).

Second, in a study of thirty-three

myeloma patients (31), Durie el. ei- could not demonstrate a direct positive
correlation between the degree of bone involvement and the serum calcium

-
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concentration.

Finally, Ralston £t ai., in a histologically diverse series of

patients with apparent LOH, actually found an inverse correlation between the
number of bone metastases and the serum calcium level (33). All of the above
data suggest that the original notion that metastatic lesions produce
hypercalcemia purely by destroying bone as they expand is overly simplistic.
Many investigators now believe that the ability of a metastatic tumor to cause
LOH is initimately related to its production of local or paracrine factors that
have the ability to alter normal bone physiology and stimulate bone resorption
(8).

The most common mechanisms involved in LOH are those associated with
solid tumors , and the majority of solid tumors causing LOH are carcinomas of
the breast (9,13). Breast cancer is a very common form of malignancy in the
general population and anywhere from sixty to ninety percent of patients with
advanced disease have skeletal metastases (32,34-36). Thirty percent of all
breast cancer patients develop hypercalcemia ( 32).

As in most MAHC,

hypercalcemia in breast cancer is caused by increased bone resorption (9,15).
There is evidence that this may occur on the basis of increased osteoclast
numbers and activity (25), or that it may occur through the direct resorption of
bone tissue by malignant cells (28). Galasko and Bennett (26,37) have suggested
that, in fact, both these mechanisms may play a part. However, they feel that
osteoclastic bone resorption is quantitatively the more important process.
It seems likely that osteoclast activation in LOH is mediated by locally
active, diffusible factors (8). Galasko and Bennett (37) initially suggested that
this factor(s) might be PGE2. It is known that PGE 2 is a potent stimulator of in
vitro bone resorption (38), and it has been shown that tumor cells can secrete
PGE2 (39).

Furthermore, co-culture experiments have demonstrated that
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prostaglandin release by tumor cells in culture has the ability to cause
resorption in adjacent bone organ cultures (40-42). Another possibility put forth
by Mundy and Martin (9) is that these local diffusible factors are produced not by
the tumor, but by lymphocytes and/or monocytes attracted to the metastatic site
by a cellular immune response induced by the tumor. As will be discussed below,
activated lymphocytes release lymphokines with potent in vitro bone-resorbing
activity. Monocytes have been shown both to release prostaglandins (43) and also
to resorb bone directly (44,45).
All of the mechanisms mentioned above may play some role in the
development of hypercalcemia associated with solid tumor skeletal metastases.
At this time, it is not known which one(s) plays the most important role. A more
complete understanding awaits further elucidation of both normal bone
physiology and those alterations occurring in and around metastatic lesions.
The other group of malignancies associated with LOH is the hematologic
cancers.

In Myers' series on MAHC (13), this group comprised 20% of all

hypercalcemic cancer patients.

Multiple myeloma is the most commonly

occurring tumor in this group.

Most patients with myeloma suffer from

extensive bone destruction, either in the form of discrete punched-out lesions or
diffuse osteopenia (9).
hypercalcemic (46).

Twenty to thirty percent of those patients become

The mechanism of LOH in multiple myeloma is better

understood than that associated with solid tumors.

It seems to be associated

with the production of a family of osteoclast activating factors (OAFs) by the
malignant cells. OAFs are a group of lymphokines that have been shown to cause
bone resorption in in vitro bioassays (49).
Histological studies have demonstrated that hypercalcemia in myeloma is
associated with markedly increased osteoclast numbers and activity (47,48).
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Since it was known that activated lymphocytes produce bone-resorbing factors
(49) and since myeloma cells are descended from B lymphocytes, Mundy and his
associated reasoned that myeloma cells might also produce these bone-resorbing
factors. They subsequently showed that tissue culture medium conditioned by
myeloma cell lines, by aspirated bone marrow cells and by bone explants of iliac
crest, all taken from patients with multiple myeloma,contained bone-resorbing
factors with chemical and biological characteristics similar to those of OAFs
(47,50,51). These findings are not restricted to multiple myeloma.

OAF-like

activity has been demonstrated in patients with Burkitt's lymphoma (50),
lymphosarcoma (52), and a retrovirus associated T-cell lymphoma (53,54).
Therefore, although there are reports (55,56) of lymphomas that secrete
1,25(OH)2 Vit. D systemically, it seems likely that

most

hematologic

malignancies produce hypercalcemia via the local elaboration of OAFs by
malignant cells present in the skeleton. Recently, two of these OAFs have been
identified. Interleukin 1 has been purified from myeloma cell culture medium ,
and identified as the factor responsible for in vitro
with such medium (57).

bone resorbing activity seen

Also tumor necrosis factor, another lymphokine

elaborated by myeloma cells , has been shown to posses in vitro bone-resorbing
activity (58).
Biochemically, patients harboring both solid and hematologic tumors
causing LOH generally have reduced levels of circulating immunoreactive
parathyroid hormone (iPTH), reduced concentrations of plasma 1,25 (OH^Vit. D,
normal levels of serum phosphate, and normal or reduced levels of nephrogenous
cyclic AMP (14). This pattern suggests parathyroid gland suppression, which is
expected in the face of elevated serum calcium levels.

However, it stands in
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contrast to the findings encountered in the second group of patients, those with
no skeletal metastases.

HUMORAL HYPERCALCEMIA OF MALIGNANCY
The second major pathophysiologic group consists of the squamous, renal,
urothelial and ovarian tumors which have the ability to cause hypercalcemia
without metastasizing to the skeleton.

These tumors seem to act through a

humoral mechanism. Hence, this syndrome has become known as the Humoral
Hypercalcemia of Malignancy or HHM (14). HHM is probably less common than
LOH, but its exact incidence is unclear. Stewart £i. ai. (14), in a study of fifty
consecutive patients with MAHC, found that eighty percent of them had HHM.
However, this study drew heavily from a VA hospital population and had a
correspondingly low incidence of breast cancer (6%). Bender and Hansen (10)
studied two hundred consecutive cases of bronchogenic carcinoma and found the
overall incidence of HHM to be seven percent. This represented fifty-six percent
of all patients who developed hypercalcemia in that selected population. The
largest published series on MAHC (430 cases collected over 5 years) found that
HHM accounted for thirteen percent of all patients with MAHC (13). There are no
direct observations on the incidence of HHM in the unselected general population.
Historically, the first reported case of HHM was that of a fifty-seven
year old man

with

bronchogenic

carcinoma,

hypophosphatemia. This patient was included in Gutman

hypercalcemia,

and

ai.'s 1936 paper on

serum calcium values in hyperparathyroidism, Paget's Disease and MAHC (11).

4-
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This patient had a localized area of Paget's disease in his right femur, but no
skeletal tumor involvement. The authors concluded:

It is believed the hypercalcemia in this case was
not due to the localized and relatively inactive
Paget's disease but to complicating factors as
yet wholly obscure.

The first clue as to the nature of these "obscure complicating factors" came from
Albright in 1941 (59).

He described a patient with a renal carcinoma and a

solitary metastasis in the right ilium.

The patient was hypercalcemic and

hypophosphatemic, both of which corrected temporarily when the patient's tumor
was treated with radiation. Combining the observations: 1. that the man was
hypophosphatemic rather than hyperphosphatemic (the expected result of any
skeletal destruction by the tumor) and 2. that the hypercalcemia was corrected
when the tumor was treated, Albright suggested that the hypercalcemia resulted
from a tumor-derived humoral factor.

Specifically, he thought the tumor might

be producing parathyroid hormone (PTH).
Following Albright's paper, there were occasional similar case reports
(60). However, the next milestone in the characterization of HHM as a distinct
entity came in 1956. Conner, Thomas, and Howard (61) reported two patients
with hypercalcemia and hypophosphatemia associated with lung cancer. In both
patients, surgical resection of the tumor brought about the normalization of
serum calcium and phosphate levels. In one of the patients, tumor recurrence
four months later was accompanied by the recurrence of the hypercalcemia and
hypophosphatemia. Both patients were shown to have histological evidence of
excessive bone resorption in sites uninvolved by tumor. Later that same year,
Plimpton and Gellhorn reported similar results (20). They described ten patients
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who also had hypercalcemia and hypophosphatemia in association with various
malignancies. None of the ten had skeletal tumor involvement as assessed by
roentgenographic survey and/or autopsy observations, and all had normal
parathyroid glands as assessed by neck exploration and/or autopsy examination.
Three of the ten patients underwent resection of their cancer which resulted in
prolonged normalization of serum calcium and phosphorus values. One of these
three suffered a recurrence and subsequently experienced a return of her
hypercalcemia.

Taken together, these two papers documented a direct link

between the presence of hypercalcemia and the extra-skeletal primary tumor in
the patients studied. Both sets of authors concluded that there exists a subset
of patients with MAHC in whom excessive bone resorption is caused by a humoral
mechanism, and not by local osteolytic events.
The

humoral

syndrome,

which

became

known

as

"ectopic

hyperparathyroidism" or "pseudohyperparathyroidism" (62,63) was considered a
rare entity until Lafferty published the first large series of patients in 1966
(12). The author defined pseudohyperparathyroidism as the the occurence of
hypercalcemia accompanied by hypophosphatemia associated with a malignancy
having no skeletal metastases.

He described sixty-seven such patients, fifty

collected from the literature and seventeen previously unpublished cases from
the University Hospitals of Cleveland.

The paper made several important

observations. First, the author observed that this was not a rare entity. In fact,
it was the third most common cause of hypercalcemia at the University Hospitals
of Cleveland. Second, he defined the histological group of neoplasms (described
earlier) with which the syndrome occurrred. Third, by documenting the reversal
of hypercalcemia with surgical resection in twenty patients, he reaffirmed the
earlier data (20,61) demonstrating the presence of a humoral mechanism. Last,
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he observed that the combination of hypercalcemia and hypophosphatemia was
not unlike that seen in patients with primary hyperparathyroidism. As suggested
earlier by Albright (59), Lafferty argued for the production of ectopic PTH as the
pathogenetic mechanism.
Lafferty's paper provided an impetus that began an earnest search for the
humoral factor or factors causing HHM. This quest has come to dominate the
literature on the topic.

Since 1966, advances in technology have also allowed a

more complete description of both the biochemical profile and the process of
bone resorption associated with the syndrome. It is worthwhile examining both
of these before discussing the proposed pathogenetic factors.
Perhaps the most definitive biochemical characterization of HHM came
from Stewart el. al. in 1980 (14).

The investigators studied fifty consecutive

patients with MAHC. They compared serum calcium levels, serum phosphorus
levels, nephrogenous cyclic AMP (NcAMP) excretion, tubular phosphorus
thresholds, fasting calcium excretion and plasma 1,25 (OH)2Vit. D concetrations
in patients with HHM to those encountered in normocalcemic cancer patients,
patients with primary hyperparathyroidism (HPT) and patients with LOH. They
found a similar degree of hypercalcemia in patients with HHM, HPT, and LOH.
Serum phosphorus levels were low to low normal in patients with HHM and HPT,
but were normal in patients with LOH. Likewise, the renal phosphorus threshold
was depressed in patients with HHM and HPT and within normal limits in patients
with LOH. Fasting calcium excretion was elevated in patients with HHM and in
those with LOH. Both groups had markedly higher values than patients with HPT
or normocalcemic cancer patients. Patients with HHM and LOH had depressed
concentrations of plasma 1,25(OH)2 Vit. D, whereas normocalcemic cancer
patients had normal values and patients with HPT had elevated values. Finally,
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the most striking finding was the very high levels of NcAMP in patients with
HHM. These values averaged fifty percent higher than those seen in patients with
HPT,whose values were moderately elevated over those of normocalcemic
patients. In distinct contrast, patients with LOH had depressed levels of NcAMP.
The above information was valuable in three respects. First, it painted a
biochemical profile of the HHM syndrome, permitting its clinical differentiation
from HPT and LOH. Second, it described the biological effects of the putative
humoral factor. This factor increases serum calcium, tends to decrease serum
phosphorus, decreases renal reabsorption of both calcium and phosphorus, lowers
serum 1,25(OH)2 Vit. D

levels and stimulates production of NcAMP. Third, it

provided a biochemical test, NcAMP, that seems to be a marker for HHM. Elevated
NcAMP values correlate strongly with the histological tumor types associated
with HHM as previously described by Lafferty (12) and others (13,15,20,24).
As in LOH, hypercalcemia in HHM is ultimately caused by increased bone
resorption. Evidence from both human (25) and animal studies (21,22) has shown
that this occurs as a result of an uncoupling of osteoblast and osteoclast
activity.

Normally, the activities of osteoblasts and osteoclasts are tightly

coordinated so that, despite the continuous and extensive flux of calcium ion
between the skeleton and the extracellular fluid, there is no net change in the
overall calcium content of either one (5).

Likewise, in several metabolic bone

diseases such as HPT, secondary hyperparathyroidism associated with renal
failure, and Paget's disease, there is increased bone turnover, but both osteoblast
and osteoclast activity increase in a coupled fashion. The balance between the
two processes is maintained (25,64).

In contrast, in HHM the balance is

disrupted. Stewart gt a!. (25) performed detailed histological and quantitative
histomorphometric studies of seven patients with HHM. They found markedly
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stimulated osteoclast function, as evidenced by an increased osteoclast surface,
in the face of markedly depressed osteoblast function, as evidenced by a reduced
osteoblast surface, osteoid surface, and osteoid volume. Hence, it seems that
the humoral factor causing HHM is able to uncouple the normal concert between
those two bone cells, increasing osteoclastic bone resorption and decreasing
osteoblastic bone formation.
The identity of the factor responsible for HHM has sparked much interest.
Early reports on HHM (12,59-63) all stressed the biochemical constellation of
hypercalcemia and hypophosphatemia.

Since these were known effects of

parathyroid hormone,Albright (59) and later Lafferty (12) invoked the idea of
ectopic PTH production in the tumors as the mechanism for HHM. This concept
persisted for some forty years, but it is now well established that native PTH is
not the responsible factor. There are three lines of evidence that support this
conclusion.

First, when the syndrome was more fully characterized

biochemically (14), it became obvious that although the clinical syndrome shares
some features of HPT,

it is not associated with the full range of PTH target

organ responses. The factor responsible for HHM mirrors the actions of PTH in
causing bone resorption, renal phosphate wasting , and generation of NcAMP (14).
However, it lacks the ability to stimulate the conversion of 25-hydroxy-vitamin
D to 1,25 dihydroxy-vitamin D and it lacks the ability to stimulate distal tubular
calcium reabsorption (14).
The second line of evidence against PTH being the HHM factor comes from
immunoassay data. Tashjian, Levine, and Munson first reported the presence of
immunoassayable PTH (iPTH) in extracts of six tumors associated with HHM in
1964 (65).

Using a quantitative complement fixation assay, Lafferty (12)

detected iPTH in an additional 4 cases of HHM.

With the advent of
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radioimmunoassays (RIA's) for PTH, there were many studies performed that
looked for the presence of iPTH in the plasma of patients with HHM (24,66-72).
Several of these reports are instructive. Using an RIA system that was specific
for the C-terminal region of porcine PTH and which displaced 131 l-labelled
bovine-PTH, Benson gtal. (69) reported the presence of iPTH in the serum of 95%
of 108 unselected patients with HHM (the majority of whom, 60, had HHM). Five
of these patients had elevated iPTH values, while the rest had iPTH
concentrations in the normal range.

The authors argued that in the face of

hypercalcemia iPTH values should be suppressed, so that values within the
"normal range" actually represented an elevation. Powell el. ai- (68) and Stewart

eta!- (14) used multiple RIA's with several different antisera directed at regions
spanning the entire length of the PTH molecule, including biologically active and
inactive native PTH and PTH fragments. Powell and associates were unable to
detect iPTH in any of the eleven patients they studied. Stewart £t al- found lownormal to undetectable mean iPTH levels in their HHM population.
Conflicting results such as this led to some argument (69) and a great
deal of speculation about the nature of the PTH secreted by the tumors (71) or
whether the tumors secreted PTH at all (68).

Despite the confusion, two facts

became established. First, results varied with different immunoassay systems
(5,68,69).

Antibodies with specificity for different parts of the PTH molecule

seemed to give different results. Second, when iPTH was detected, it was noted
that the serum levels did not vary with serum calcium concentrations as would
have been expected. Serum iPTH was consistently lower in patients with HHM
than it was in patients with HPT (67,69), and although there was a correlation
between increasing calcium levels and increasing iPTH levels in HPT, no such
correlation was evident in HHM.

-
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These data became more fully interpretable only with the addition of
several observations on the nature of native PTH secretion.

First, it became

evident that serum iPTH is a heterogeneous mixture of both biologically active
and inactive fragments (71,73-79).

Second, it was noted that there is a

nonsuppressible component of iPTH secretion that operates even in the face of
hypercalcemia (80). Third, it was discovered that hypercalcemia changes the
composition of the circulating iPTH in serum.

It increases the proportion of

biologically inactive C-terminus PTH fragments and it decreases the proportion
of biologically active N-terminus fragments (81,82).

These facts suggest an

explanation for the disagreement between the studies.

By virtue of its low

concentration and its lack of correlation with serum calcium levels, the iPTH
measured in the patients with HHM most likely represents the nonsuppressible
segment of PTH secretion and the accumulation in plasma of biologically inactive
C-terminus fragments. The variation seen with different assays was probably
based on whether or not they could recognize these biologically inactive
fragments. Benson

al. (69) unknowingly anticipated this conclusion. They

pointed out that their high incidence of detecting iPTH relied on their use of a
more "sensitive" RIA employing specificity for the C-terminal end of PTH.
Further support for this interpretation also comes from Broadus and Stewart (5)
and Mallette el. al. (83). Both sets of investigators have recently measured serum
iPTH in patients with HHM using a sensitive PTH-RIA with mid-region and Cterminus specificity. Both studies found low concentrations of iPTH that did not
correlate with serum calcium concentrations but did correlate with serum
creatinine concentrations. This suggests that any iPTH detected in patients with
HHM can be explained by retained C-terminal PTH fragments which accumulate
following the development of azotemia (84).
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The last and most powerful piece of evidence arguing against PTH as the
humoral factor in HHM comes from mRNA hybridization data. Simpson et al. (85)
used radiolabelled PTH cDNAto probe Northern blots of mRNA extracted from
five human tumors and three animal tumors associated with HHM. The authors
claimed that they could detect PTH mRNA in as little as 100 ug of control
parathyroid tissue using their hybridization scheme. However, they were unable
to detect PTH mRNA in as much as 100 mg of tissue from any of the HHM tumors.
Therefore, since the probe used in this study contained the coding and flanking
sequences for PTH, it is very unlikely that the factor responsible for HHM shares
a significant portion of its primary amino acid sequence with PTH or that the
HHM-factor is a product of the PTH gene. These results have recently been
duplicated by Insogna £t al in a Leydig cell tumor rat model of HHM (22).
It is evident that HHM is not caused by the ectopic production of PTH. The
exact nature of the factor causing this syndrome is not known at present. The
leading contenders are prostaglandins, transforming growth factors, and
peptide(s) structurally dissimilar to PTH, yet able to stimulate certain PTH
receptors.

The evidence for each of these possibilities will be discussed

separately below.

Prostaglandins
Prostaglandins were first shown to resorb bone in 1970 by Klein and
Raisz (40). Using a fetal rat long bone assay (86), these investigators showed
that prostaglandins of the E series had potent in vitro bone-resorbing activity,
similar to that of PTH.

This observation prompted

speculation

that
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prostaglandins might play a role in HHM. It is now established that PGE2 is an
important humoral factor in two animal models of HHM.
Work by Tashjian and his group has implicated PGE2 as the humoral
mediator of hypercalcemia in the mouse HSDM

1

fibrosarcoma and in the rabbit

VX2 carcinoma. The HSDMi fibrosarcoma is a transplantable tumor that neither
metastasizes to bone nor locally invades bone, but causes hypercalclemia (8,87).
The hypercalclemia is reversible with surgical resection of the tumor, indicating
a humoral mechanism. Mice bearing this tumor have elevated plasma levels of
PGE2 and its longer-lived metabolite 13,14 dihydro-15-keto-PGE2 (88-90).

It

has been shown that HSDMi cells produce large quantities of PGE2 (88) and that
tumor extracts as well as tumor-conditioned medium contains bone-resorbing
activity that can be accounted for quantitatively by the PGE2 content of the
tumor or medium (88,91).

Finally, indomethacin, 5,8,11,14-eicosatetraynoic

acid, and hydrocortisone, all powerful inhibitors of PGE2 synthesis in HSDMi
cells, have been shown:

1.

to lower plasma concentrations of PGE2, its

metabolites, and serum calcium and 2. to decrease in parallel the PGE2 content
and the bone-resorbing activity of these tumors (88-92).
The VX2 carcinoma, also a transplantable tumor, causes hypercalcemia in
rabbits.

This tumor does not metastasize to bone, but it produces a bone-

resorbing factor that causes histomorphometric changes reminiscent of human
HHM (91,93). Rabbits harboring this tumor show elevated levels of PGE 2 and its
metabolite 13,14-dihydro-15-keto PGE2 in both plasma and venous drainage of
the tumor (94-96).

Tashjian et. al. have reported that indomethacin and

hydrocortisone prevent the rise in plasma levels of both compounds and reduce
the levels of PGE2 and bone-resorbing activity present in tumor extracts or VX2
cell culture medium (91,94,95).

Furthermore, they claim that continuous
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treatment of the rabbits with indomethacin from the time

of tumor

transplantation prevents the development of hypercalcemia (91,94). Recently,
Doppelt

ai. (97) have called these results into question. In sharp contrast to

the above results, they observed that on a normal calcium diet, oral indomethacin
treatment neither prevented the development of hypercalcemia nor did it lower
the serum calcium level once hypercalcemia was present. Also, the investigators
were not able

to

prevent

the

development

of

hypercalcemia

with

dichloromethylene diphosphonate, a potent inhibitor of bone resorption. The only
way they were able to reverse the hypercalcemia was to feed the rabbits a
calcium-free diet. Hence, despite Tashjian et al's findings, the mechanisms of
hypercalcemia in this model are not fully understood.

It is likely that intestinal

calcium hyperabsorption is the major pathophysiologic feature of the syndrome
in these animals.
Despite the compelling evidence for a causitive role in the HDSM -j
fibrosarcoma and the suggestion of a contributing role in the VX2 rabbits,
prostaglandins seem to have little if any role as humoral mediators of
hypercalcemia in humans (8,9). These compounds were originally proposed to be
mediators of HHM in humans based on two facts. It was known that many human
tumors produce prostaglandins, PGE2 in particular (41). Also, there were several
early case reports claiming a correlation between hypercalcemia and elevated
plasma PGE2 levels in patients with renal carcinomas (98,99). Seyberth et al.
(100) furthered this speculation when they reported elevated levels of 7 ahydroxy-5,11 diketotetranorprostane-1,16 dioic acid (PGE-M), the major urinary
metabolity of PGE2> in twelve of fourteen patients with MAHC. However, seven
of fifteen normocalcemic patients with solid tumors also had elevated levels,
calling into question the specificity of these findings with

regard to
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hypercalcemia. Further experience (101-103) has shown that tumor production
of prostaglandins does not correlate well with calcium levels and that
circulating levels of PGE2 and/or its metabolites are too low to account for the
level of bone resorption necessary to cause hypercalcemia.

Finally, despite a

few reported successes (103,104), prostaglandin synthesis inhibitors such as
indomethacin have not been efficacious in treating MAHC (9). The evidence now
suggests that prostaglandins may play a greater role in controlling some local
aspects of bone formation or resorption.

For example, Minkin si. al. have

demonstrated that prostaglandin synthesis inhibitors can suppress the in vitro
bone resorption caused by systemic factors released by tumors (105). However,
the data clearly shows that prostaglandins have no general role as the systemic,
humoral bone-resorbing factor causing HHM.

Transforming Growth Factors
In recent years Mundy and his colleagues have proposed the transforming
growth factors (TGFs) as possible etiologic agents responsible for HHM. This
proposal is based on two observations. First, Tashjian and Levine (106), using
the mouse calvarium assay and Raisz £l. a!- (107), using the fetal rat long-bone
assay

have demonstrated that epidermal growth factor (EGF) is a potent

stimulator of bone resorption in vitro.

Second, there is evidence that many

human tumors produce TGFs, a family of factors that share biological activities
with EGF, including the ability to interact directly with the EGF receptor
(48,108-110).

Briefly, the characteristics of TGFs include the ability to

stimulate cell growth and replication (mitogenesis) and the ability to
"transform" normal cell lines (111). "Transformation" is defined as the loss of
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density-dependent growth inhibition and development of anchorage-independent
growth, detected by the ability to form colonies in soft agar (112). TGF- a's are
those which can compete with EGF for binding to its receptor and can
independently stimulate anchorage-independent cell growth (113). TGF-B's, on
the other hand, require the presence of EGF to stimulate anchorage-independent
growth, and they do not compete with EGF for receptor binding (113). Mundy and
his group have presented evidence suggesting pathogenetic roles for both TGF-a
andTGF-B in HHM.
The evidence concerning TGF-a comes from work done with a Leydig cell
tumor. This tumor causes hypercalcemia in rats and has been shown to be a
reliable model for HHM (8).

Ibbotson £i. ai- (114) reported that both tumor

extracts and conditioned medium from tumor cell cultures contain a boneresorbing factor that shares certain physical characteristics with TGFs.

It is

acid stable, sensitive to reducing agents and sensitive to trypsin. They were
able to demonstrate co-elution of bone-resorbing activity, mitogenic activity,
and soft agar colony-stimulating activity on gel filtration chromatography of
tumor extracts and tumor conditioned medium.

The gel-filtration fractions

containing bone-resorbing activity also contained a factor which is able to
compete with labelled EGF for binding to the EGF receptor. Further studies have
demonstrated that the addition of EGF receptor antiserum to the fetal rat bone
resorption assay inhibits the resorption usually seen with tumor conditioned
medium and with EGF, but not that seen with PTH (115). This suggests that bone
resorption in the rat Leydig cell tumor model may involve the EGF receptor,
supporting the possibility of an etiologic role for TGF-a .
The evidence concerning TGF-B comes from the hypercalcemic variant of
the Walker Rat Carcinosarcoma,also shown to be a valid model of HHM (8). As in
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the Leydig cell model, D'Souza £i. ai. found that the bone-resorbing activity
present in tumor extracts and tumor-conditioned medium shares certain physical
characteristics with TGF,including stability to acid and heat and sensitivity to
the reducing agent, dithiothreatol (DTT) (116). They also demonstrated the co¬
elution of bone-resorbing and soft agar-stimulating activities on gel filtration
chromatography (116).
two respects.

However, the TGF activity is different in this model in

It does not seem to inhibit labelled EGF from binding to its

receptor and it requires the presence of EGF to cause cell transformation. These
observations form the basis for the authors' suggestion that the activity is a
TGF-3.
Evidence for the role of TGFs in human HHM is limited to experience with
two tumors, a renal cell carcinoma and a squamous cell lung carcinoma. In both
of these tumors, bone-resorbing activity has been shown to have the previously
mentioned physical characteristics, stability in acid, sensitivity to DTT, and
sensitivity to trypsin, which are also seen TGFs (117,118). Furthermore, Jacobs
St ai. have reported that an mRNA isolated from the renal cell tumor and injected
into a xenopus ooctye protein translation system stimulates the production of a
factor or factors that binds to the EGF receptor (118).
It is impossible to prove categorically whether or not the bone-resorbing
and the TGF activities described in these studies are one and the same until
these activities are purified to homogeneity.

The attempt to accomplish this

purification is currently in progress. When and if it is susccessful, it will allow
the elucidation of any connections between the bone-resorbing activity, the
growth factor activity, and the adenylate cyclase activity (to be discussed next)
associated with HHM.
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PTH-like Peptides or Adenvlate-Cvclase Stimulating Factor(s)
There is growing evidence that tumors associated with HHM produce a
peptide or peptides able to specifically interact with selected parathyroid
hormone receptors.

As reviewed earlier, the evidence against PTH as the

pathophysiologic culprit in HHM is strong.

Also the preliminary molecular

biology data (22,85) makes it unlikely that the HHM factor(s) (HHM-F) physically
resembles PTH, at least with respect to its primary protein structure. However,
its ability to resorb bone (25) and to stimulate the proximal renal tubular
adenylate cyclase system (14) suggests that HHM-F must share some effector
mechanisms with PTH. Further support for this notion is supplied by Goltzman
and Stewart (119,120), who have demonstrated a third bioactivity held in
common between PTH and HHM, one which is not directly related to the clinical
syndrome. They showed that serum from patients with HHM contained a factor
which could stimulate the PTH-sensitive proximal tubular glucose-6 -phosphate
dehydrogenase complex in an in vitro cytochemical assay.
Much of the evidence for the existence of biologically active PTH-like
peptides in patients with HHM rests on the observation that these patients have
elevated levels of NcAMP. It is assumed that these elevated levels result from
the ability of HHM-F to stimulate the PTH mediated proximal renal tubular
adenylate cyclase system. It is helpful to look more closely at this observation
and this assumption. Fifty to sixty percent of the total urinary cAMP content is
derived from the renal excretion of plasma cAMP (121,122). The remainder is
produced by the kidney, largely in response to circulating PTH, which acts at the
proximal tubular adenylate cyclase system (122). Broadus £l. &[. have shown that
the renally produced PTH-sensitive element of urinary cAMP can be quantified by
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expressing total urinary cAMP as a function of the glomerular filtration rate and
by subtracting the filtered load of cAMP (123) .

This expression, known as

NcAMP or nephrogenous cyclic-AMP, correlates well with iPTH levels, and its
elevation has become a marker for elevated levels of circulating PTH. Several
groups have investigated the levels of NcAMP associated with HHM. KukrejafiJ. si(124) found elevated NcAMP levels, yet normal iPTH levels, in patients with lung
cancer. Rude si. si- (121) reported increased NcAMP levels in a series of patients
with MAHC as compared to normocalcemic cancer patients. They found that these
elevations were most likely to be found in patients with squamous tumors or
renal cell carcinomas (121).

Finally Stewart

(14) observed a clear

dichotomy between elevated NcAMP levels (similar to patients with HPT) in
patients with HHM and depressed levels in patients with LOH.

The findings were

so striking that the authors argued for a redefinition of the syndrome of HHM
based on NcAMP. They suggested that those patients with tumors of expected
histology and with elevated NcAMP levels be classified in the HHM group even
though they might have limited skeletal metastases.
After having established elevated NcAMP as a reliable marker,
investigators began looking for an adenylate cyclase stimulating factor(s)
(ACSF) in extracts of tumors associated with HHM.

Stewart el. ai. first

accomplished this in 1983 (120). These investigators employed two in vitro
systems to probe for PTH-like activity:

1.

a canine renal cortical membrane

adenylate cyclase assay measuring proximal tubular adenylate cyclase
stimulating activity (ACSA) and 2. the PTH cytochemical bioassay mentioned
above, which measures PTH-sensitive renal tubular G-6-PD stimulating activity.
They demonstrated dose-dependent ACSA and G-6-PD-stimulating activity in
four of five tumor HHM extracts tested.

Control extracts from tumors of nine
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normocalcemic cancer patients and one patient with LOH showed either the
absence of such activity or only marginal ACSA (3 patients).

PTH-like

bioactivity was abolished in both assays in a dose-dependent fashion by the
addition to the assay of [Nle 8-18’ Tyr 34] bPTH (3-34) amide, a synthetic
analogue and specific PTH receptor antagonist (120). This observation strongly
suggests that some factor in the extracts was specifically interacting with PTH
receptors. However, preincubation of the tumor extracts with PTH antiserum did
not alter the bioactivity seen in either assay system, confirming that the
stimulation is not due to PTH. Finally, the investigators also demonstrated that
the PTH-like bioactivity eluted from gel filtration columns at an apparent
molecular weight of 28,000 daltons, a molecular weight much larger than that of
PTH
Since this initial report, tumors from many more patients have been
examined for the presence of ACSA. In a recent publication of their laboratory's
aggragate experience (125), Stewart si- ai. reported the presence of dosedependent renal cortical ACSA in eighteen of twenty tumors associated with
HHM.

In contrast only four of thirty-seven control tumors (20 tumors from

normocalcemic patients, 7 tumors associated with LOH, 10 nonmalignant tissue
samples) were reported to contain any detectable ACSA. In addition, extracts
from many of these tumors as well as conditioned medium from cultured tumor
lines associated with HHM, have been shown to stimulate PTH-sensitive
adenylate cyclase production in clonal osteosarcoma cells (125,126). As in the
renal cortical membrane assay, this cAMP production is inhibitable by the PTH
receptor antagonist [Nle 8-18, Tyr 34] bPTH (3-34) amide (126).
Investigators in another laboratory have confirmed the pesence of ACSA
in tumors associated with HHM (127).

Strewler and his associates have
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transplanted a cultured human renal cell carcinoma line into nude mice. The mice
develop HHM, and conditioned medium for the cell cultures contains ACSA as
determined in the renal cortical membrane assay. This ACSA is dose-dependent
and inhibitable with the PTH antagonist mentioned previously.

Final support

comes from animal data. ACSA has been demonstrated in the following models of
HHM: a carcinogen induced mouse squamous tumor (21), the Walker rat
carcinosarcoma 256 (126), the H-500 rat Leydig cell tumor (126,128), and a
naturally occurring canine lymphosarcoma (129).
As established before, HHM is ultimately caused by increased bone
resorption (25). The above data is strong circumstantial evidence that this ACSA
is associated with HHM.

However, to implicate it as the causative factor(s)

necessitates showing that it also has bone-resorbing activity. Several groups
have recently accomplished this.

Klein £l. a[. have shown that conditioned

medium from a human renal cell tumor line causes bone resorption in the fetal
rat long bone assay (130). Furthermore, both Klein £i. al- (130) and Stewart at al(125) have demonstrated co-purification of ACSA and bone-resorbing activity in
initial partial purification schemes.

Klein al.

al-

observed co-elution of these

activities from a gel filtration column, which achieved a 20-fold purification of
the ACSA. Stewart

al-_2l-

have purified the ACSA from tumor extracts much

further (some 4800-fold) using reverse phase HPLC and have still obseved potent
bone-resorbing activity associated with the ACSA.

Similar observations have

been made in two of the animal tumor models of HHM shown to possess ACSA.
Conditioned medium from the Walker rat 256 carcinosarcoma has been shown to
possess bone-resorbing activity (126), and both bone-resorbing activity and
ACSA have been shown to co-migrate on gel filtration of conditioned medium
from Rice H-500 rat Leydig cell tumor lines (128).
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As with the TGF activity, until the ACSA in purified to homogeneity, it
will be impossible to ascertain whether the cAMP-generating activity and the
bone-resorbing activity reside in the same molecule. However, the data gathered
thus far seem to anticipate this result.
Final support for the involvement of an adenylate cyclase-stimulating
factor(s) in HHM comes from recent work by Merendino and Stewart. Since many
tumors causing HHM are of squamous epithelial origins (14), these investigators
tested for the presence of ACSA in culture medium from non-malignant human
keratinocytes. They demonstrated that,indeed, these cells produced a factor or
factors with dose-dependant ACSA in the rat osteosarcoma cell assay (132).
Furthermore, this activity is inhibitable by the PTH receptor antagonist, [Nle
8,18,Tyr34] bPTH (3-34) amide, in a fashion similar to the ACSA associated with
HHM tumor lines. Subsequent experiments have shown that this factor or factors
also possesses bone-resorbing activity in the fetal rat long bone assay (Stewart,
unpublished observations). Currently, it is not known whether it is by chance or
by design that a normal keratinocyte product has the ability to interact with PTH
receptors and to cause bone resorption.

However, it suggests that the non-

regulated production of such a factor(s) by malignant squamous epithelial cells
and its release into the general circulation may be a pathogenetic event in HHM.
Partial purification of this ACSA has allowed the elucidation of several
of its physical characteristics.

First, it is a protein.

Several studies have

shown the loss of ACSA and bone-resorbing activity when samples were treated
with trypsin (125-128,130). Gel filtration chromatography suggests that it has
an apparent molecular weight of approximately 30,000 daltons (21,22,130,131).
However, based on SDS PAGE results, a molecular weight of 15,000 seems more
likely (Burtis W and Stewart A, unpublished observations).

Finally, the protein,
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at least in its partially purified form, has been shown to be stable under
conditions of dilute acid, freezing and thawing, lyophilization, and boiling at
100°C for up to fifteen minutes (120)
It was in the setting of attempts to isolate and purify the ACSF discussed
above that the studies to be described shortly were undertaken.

They are a

series of experiments exploring different physical characteristics of partially
purified ACSF. The behavior of ACSF was examined under oxidizing and reducing
conditions, and at different pH's. It was subjected to cyanogen bromide digestion
in an attempt to generate an active fragment.

Finally, the possibility that it

might be a glycoprotein was explored. The goals of these experiments were
three-fold: 1. to characterize the molecule(s) more fully, 2. to provide guidelines
on handling the increasingly pure protein, and 3. to compare its physical
characteristics to those reported for the TGF activity associated with HHM.

Adenylate Cvclase Assay

PTH-like activity was measured using a modified version of the canine
renal cortical membrane adenylate cyclase assay described by Nissenson et-

si-

(133). The assay measures the conversion of 32P-ATP to 32P-cAMP triggered by
the stimulation of a PTH receptor-mediated adenylate cyclase system contained
in a renal membrane preparation.
prepared as follows.

Purified renal cortical membranes were

Cortical tissue was dissected from a freshly removed

canine kidney and homogenized. Membranes were separated from other cellular
elements by sucrose density centrifugations, after which they were resuspended
in 0.25 M sucrose, 10mM EDTA and 5.0 mM Tris-HCI, pH 7.5 at a protein
concentration of 3.2 mg/ml. The membranes were stored in aliquots at -80 °C
until used in the assay.
The reaction mixture or "cocktail" consists of 60 microliters per tube of
50 mM Tris-Hcl (pH 7.4), 5 mM Mg Cl2, 10 mM KCI, 1 mg/ml BSA, 1 mM EGTA, 2
mM DTT, 0.11 pg/ml creatine kinase, 5 mM creatine phosphate, 1 mM unlabelled
cAMP, 10 pM 5' guanylyl imidodiphosphate, 6 pg canine renal cortical membrane
protein and approximately 500,000 cpm 32P-ATP. The creatine phosphate and
creatine kinase constitute an ATP regeneration system, and the unlabelled cAMP
is added to retard degradation

of the newly formed

32P-cAMP by

phosphodiesterase. 5' guanylyl imidodiphosphate is a hydrolysis-resistant GTP
analogue which has been shown to increase greatly the sensitivity of adenylate
cyclase to PTH (134,135).

The reactions were initiated by addition of 10
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microliters of bPTH (1-34) [Beckman Bioproducts, Palo Alto, CA] as a standard,
10 microliters of 5 mM acetic acid/ 0.5 mg/ml BSA (HAc/BSA) as a basal, or 10
microliters of experimental sample, all added at 0°C.

The reactions were

allowed to proceed at 30°C for 30 minutes and were then terminated with the
addition, at 0°C, of 100 microliters of 2 mM ATP, 0.5 mM cAMP, and 10,000 cpm
3HcAMP as a recovery standard. Reaction tubes were then boiled for 3 minutes at
100°C, diluted with 800 microliters of water and centrifuged at 3000 X g for 10
minutes.
32P-cAMP generated in the reactions was separated from unused 32P-ATP
using the chromatographic method of Salomon

al. (136). The reaction mixture

(1 ml.) was applied to Dowex AG 50 W-X4 (200-400 mesh) cation exchange
columns and eluted with water onto Alumina columns. The cAMP was then eluted
from the alumina with 5 mis. of 0.1 M Imidazole and collected in scintillation
vials containing 15 mis of Optiflour liquid scintillation fluid

(Packard).

Radioactivity was measured with a dual isotope 3H/32P program and all values
were corrected for 3H cAMP recovery. Results are expressed as the percentage
increment of 32P counts over basal activity.

Source of ACSF

The adenylate cyclase stimulating factor(s) or ACSF used in these
experiments was extracted from a breast carcinoma. The patient was defined as
having HHM by virtue of an elevated serum calcium (12.9 mg%, nl. 9.5-10.6),
absence of any skeletal metastases on bone scan or at autopsy, elevated
nephrogenous cAMP (4.66 nmol/dl GF, nl .5-2.5) and normal commerical

31

immunoreactive PTH and plasma 1,25(OH)2 vitamin D levels. Four and one half
grams of tumor tissue obtained at autopsy was subjected to a three step
purification scheme.

First, it was extracted with acid/urea as previously

reported (120). Briefly, tissue was homogenized in a Waring blender in 0.1 M Tris
HCI, pH 7.4 at 0°C and then centrifuged for 15 minutes at 27,000 X g. The pellet
was then extracted in 8 M urea, 0.2 M HCI and 0.1 M cysteine for 1 hour. The
resulting extract was centrifuged for 15 minutes at 27,000 X g and the
supernatant was dialyzed against 12 liters of water over 24 hours.

The

dialysate was subsequently divided into aliquots and lyophilized. The second
step was an ethanol-sodium chloride extraction (125). The lyophilized acid/urea
extract was resuspended in 10 mM acetic acid containing 100 mM NaCI. Ice cold
ethanol was added to a final concentration of 20% (vol:vol). This mixture was
kept on ice for 15 minutes, being occasionally vortexed, and was then
centrifuged at 16,000 X g for 15 minutes. The supernatant was removed, frozen
on dry ice, and lyophilized. The third and final step in the partial purification
consisted of reverse phase HPLC. Samples of the ethanol-NaCI extract were
suspended in 0.1% trifluoroacetic acid and were applied to a Vydac Cie reverse
phase column (Separation group, Hesperia, CA).

Using a Waters Associates

(Milford, MA) mode! 680 controller, U6-K injector, two 510 pumps and a 440
detector, the column was exposed to a gradient of acetonitrile in 0.1%
trifluoroacetic acid at a flow rate of 1.0 ml per minute. The partially purified
ACSF represents five pooled 2-ml fractions collected from 30% to 36%
acetonitrile.

These fractions corresponded to the only HPLC fractions with

significant cyclase stimulating and bone resorbing activity (125). The pooled
fractions were divided into 20 microliter aliquots, frozen on dry ice, lyophilized,
and stored at -70°C until used in experiments. These pooled HPLC fractions were
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shown to have a specific activity of 12,000

nanogram equivalents (ng.eq.) of

bPTH (l-34)/ml in the renal adenylate cyclase assay. This
approximately a 4800-fold purification

represents

over the crude acid/urea extracts

described previously (120,125,137).

Oxidation and Reduction Experiments

Bovine-PTH(l-34) and partially purified ACSF were oxidized with
hydrogen peroxide for varying lengths of time.

Sample was combined with

hydrogen peroxide at final concentrations of 200 ng/ml of PTH (1-34) or 2.4
ng.eq./ml ACSF and 0.044 M H2O2, respectively. Reactions were allowed to
proceed at 25°C for thirty minutes, one, two, or three hours and were terminated
by freezing on dry ice, and lyophilizing. The samples were resuspended at their
initial concentrations in HAc/BSA after which they were assayed for cAMP
generating activity.
PTH (1-34) and partially purified ACSF were exposed to three different
reducing agents: B-mercaptoethanol (B-ME), Dithiothreitol (DTT), and L-cysteine.
Samples were mixed with reducing agents at final concentrations of 200 ng/ml
PTH (1-34) or 2.4 ng.eq.PTH/ml of ACSF and 300 mM B-ME, 65 mM DTT, or 130 mM
L-cysteine. The reaction was carried out at 25°C for 17 hours, after which time
the samples were placed at 0°C and assayed in the renal cAMP assay.
Partially purified ACSF was also sequentially oxidized and reduced.
Samples of HHM-F were exposed to 0.044 M H 2O2 for three hours at 25°C, frozen
on dry ice and lyophilized as described above. Samples were then resuspended in
HAc/BSA and then mixed with reducing agents to give final concentrations of 300
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mM BME, 65 mM DTT, or 130 mM L-cysteine and 2.4 ng.eq. PTH/ml of ACSF. These
reaction mixtures were incubated at 25°C for 20 hours and then assayed for
cAMP generating activity in the renal adenylate cyclase assay.

pH Experiments

PTH and partially purified ACSF were exposed to various pH's ranging from
3 to 10 in an ammonium acetate buffer system. Ammonium acetate was chosen
for its volatility. Aliquots of either ACSF or PTH in HAc/BSA were lyophilized
and then resuspended in 100 mM ammonium acetate previously adjusted to the
desired pH with either glacial acetic acid or concentrated ammonium hydroxide.
They were incubated at room temperature for 2 hours. One half of the samples
were then frozen on dry ice, lyophilized for a second time, resuspended in
HAc/BSA, and immediately assayed for cAMP generating activity. The remainder
of the samples were simply assayed for cAMP generating activity, with and
without dilutions, at the completion of their 2-hour incubation in 100 mM
ammonium acetate. Controls were treated in an identical fashion except that
HAc/BSA was substituted for the pH-adjusted ammonium acetate.

100 mM

ammonium acetate adjusted to various pH's, but without HHM-F or PTH as
agonist, was also run in the renal cyclase assay as a control.

Cyanogen Bromide Experiments
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PTH or partially purified ACSF was exposed to cyanogen bromide (CNBr)
digestion.

Sample was mixed with either a twenty-five or fifty-fold excess

(mole/mole) of CNBr dissolved in 70% formic acid and incubated at room
temperature for four hours. The reaction was terminated by the addition of ten
volumes of de-ionized water at 0°C and freezing on dry ice. The digests were
then lyophilized, resuspended in HAc/BSA and assayed for cyclase stimulating
activity. One of the digests so prepared was also run over reverse phase HPLC on
a Vydac C-|q column with a buffer gradient of 25%-35% acetonitrile in 0.1%
trifluoroacetic acid at a rate of one ml./min. Two ml. fractions were collected,
lyophilized, resuspended in HAc/BSA and assayed for cyclase stimulating
activity.

Lectin Affinity Columns

Lectin affinity columns were constructed as follows.
syringes were fitted with a pourous polystyrene plug.
Concanavalin-A (Con-A) or wheat germ lectin (WGL)

Plastic tuberculin
0.03 cc of either

covalently bonded to

Sepharose beads (Con-A-Sepharose, WGL-Sepharose, Sigma, St. Louis, Mo.) was
placed on top of the polystyrene. Samples were subsequently added to the open
end of the syringe, and were eluted with the aid of a brief spin in a table-top
centrifuge.
Loading buffer for the Con-A columns consisted of 125mM sodium
chloride, 12.5mM ammonium acetate, ImM calcium chloride and ImM manganese
chloride adjusted to a pH of 6.0.

Con-A eluting buffer consisted of the loading

buffer plus 500mM a -D-methyl-mannoside. Loading buffer for the WGL column
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consisted of 125mM sodium chloride and 12.5mM ammonium acetate adjusted to a
pH of 7.0.

WGL eluting buffer consisted of the loading buffer plus 0.2 M N-

acetyl-D-glucosamine.
Con-A binding experiments were performed in the following fashion.
First, columns were washed with 5 mis of loading buffer, after which sample
was added. 125 l-labelled

B - HCG (kindly provided by the Gyn. Endocrinology

Laboratory, YNHH) was used as a positive control. A 100 ul aliquot of loading
buffer containing 0.66 ng. of125l-B -HCG having 100,000 cpm was applied to the
column.

Fifteen minutes was allowed for binding and the loading buffer was

eluted and collected. The column was washed seven times with 100 ul of loading
buffer; each wash was collected and saved.
performed:

Seven eluting steps were then

100 ul aliquots of eluting buffer were added to the column, were

allowed to remain for fifteen minutes, and were eluted and saved. All fifteen
collected fractions (one loading sample, seven washes, seven elutions) were then
tested for the presence of 125I-S -HCG in a gamma counter. The column itself
was also counted so that recoveries could be calculated. The above experiment
was run in an identical fashion with partially purified ACSF. A 100 ul sample ,
containing 0.72 ng.eq. PTH of ACSF suspended in Con-A loading buffer, was
applied to the column. The sample loading buffer, seven washes, and seven
elutions were collected as before and were assayed for bioactivity in the renal
adenylate cyclase assay.
A similar preliminary experiment

was performed with a wheat germ

lectin column. A 0.7 ng.eq.PTH sample of ACSF, suspended in 50 ul of WGL loading
buffer, was applied to the column. Fifteen minutes was allowed for binding to
occur and then the sample buffer was eluted and saved. The column was washed
twice with 50 ul of

loading buffer, the fractions being collected and saved.
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Following these washes, a total of three elution steps were performed: 50 ul of
elution buffer was added, allowed to remain for fifteen minutes, and then eluted
and saved. Finally, the sample loading buffer, the two washes, and the three
elutions were assayed for adenylate cyclase-stimulating activity in the renal
adenylate cyclase assay.
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Renal Cortical Adenylate Cvclase Assay Standard Curves
Figure 1 shows the dose-response curves of synthetic bPTH (1-34) in the
guanyl-nucleotide amplified canine renal cortical adenylate cyclase assay
(cyclase assay).

This curve represents the averaged results from all the

individual assays performed.

As reported previously (120,125-128,137), this

dose-response curve demonstrates that the renal adenylate cyclase assay has a
minimum concentration detection limit of approximately 200 pg PTH/ml.

It is

linear over the range of 0.2 ng PTH/ml. to 20 ng. PTH/ml., and it reaches a
maximum stimulation of approximately five and one half times the basal activity
at a concentration of PTH between 20 ng./ml. and 200 ng./ml.

Figure 1 also

shows the averaged dose-response curve of the pooled HPLC - ACSF preparations
described previously. As can be seen, this curve is nearly identical to that of
bPTH(1-34). At the concentrations assayed, the curves are essentially linear.
Using these curves it is possible to extrapolate and express the HHM-derived
ACSF in PTH equivalents. Thus, a forty-fold dilution of partially purified ACSF
(representing one of the 20 u\ aliquots described in the Methods section diluted
out to 800 u\) can be shown to have an average ACSF concentration of 2.3
ng.eq.PTH/ml.

Oxidation-Reduction Experiments
In order to ascertain whether the PTH-like bioactivity could be recovered
from polyacrylamide gels run under reducing conditions, and in order to compare
it to TGFs, ACSF was exposed to reducing agents. Figure 2 shows dose response
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curves for both PTH and ACSF assayed alone or in the presence of reducing agents
as described in the Methods section. As can be seen from these figures, at the
two most concentrated dilutions, DTT seems to inhibit the cyclase assay mildly.
At these same dilutions L-cysteine profoundly suppresses cAMP formation.
However, when the reaction mixtures are assayed at greater dilutions, the curves
converge.

This demonstrates that when the assay-inhibiting effects of the

reducing agents are diluted out, neither PTH (Fig. 2a) nor ACSF (Fig. 2b)
affected by the exposure to reducing conditions.

is

Table 1 displays mean

stimulation from four cyclase assay runs of control and reduced ACSF. Again, at
concentrations in which DTT and L-cysteine do not affect the cyclase assay, the
bioactivity of the samples exposed to reducing agents is identical to that seen
with unreduced ACSF.

TABLE 1
ACSF DILUTIONS

1 : 40

1 : 80

1 : 160

1 : 320

OCMFQ - 3.316 ±0.427

2.90 ± 0.402

2.41 ± 0.390

1.82 ±0.196

*

-ME

3.651± 0.317

3.08 ± 0.405

2.4710.399

1.99 ±0.364

DTT

2.60 ± 0.055

2.2810.178

2.0010.366

1.76 ±0.215

L-CYS

0.035 ± 0.008

1.35 ±0.395

2.111 0.273

1.81 ±0.271

It was known that PTH loses its bioactivity when oxidized (139). For this
reason both PTH and the partially purified ACSF were exposed to hydrogen
peroxide. In contrast to the reducing agent experiments, it was found that both
of these molecules are sensitive to oxidation. Figure 3 shows the dose-response
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curves generated by PTH and ACSF after exposure to hydrogen peroxide (H2O2) for
varying lengths of time.

PTH bioactivity is almost completely destroyed by

exposure to 1-^02 for as little as thirty minutes (Fig. 3a). ACSF is less sensitive
to this oxidant. Residual cyclase activity is present even after 3 hours exposure
to H2O2 (Fig.3b). Figure 3c demonstrates the time courses for the progressive
loss of ACSF and PTH bioactivity upon exposure to H2O2. Again, it is seen that
ACSF is oxidized much more gradually than is PTH.
Finally, an attempt was made to reverse the loss of bioactivity seen with
oxidation by exposing the H2C>2-treated ACSF to reducing conditions. Figure 4
shows the results of this sequential oxidation and then reduction. The effect of
oxidation is not reversed by any of the three reducing conditions employed.

pH Experiments
In an attempt to determine whether exposure to different pH's affected
its bioactivity, the ACSF was incubated in 100 mM ammonium acetate adjusted
to various pH's, as described above. These experiments were prompted by the
poor recoveries of bioactivity from ion-exchange columns used in another series
of experiments with ACSF. Preliminary studies had suggested that the neutral
pH's involved in the attempts at ion-exchange chromatography might be affecting
the ACSF (Stewart, unpublished data). Ammonium acetate was the buffer used for
the ion-exchange experiments.

Because of this, and because it is volatile,

ammonium acetate was also chosen as the buffer in these experiments. Figure
5a shows the effects of this buffer system adjusted to pH’s from 3 to 10 on
basal activity in the renal cortical adenylate cyclase assay. There is a marked
inhibition of basal activity in the assay below a pH of 6. From pH's 6-9 the basal
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activity appears to be appropriate, while at pH 10 there is a marked stimulation
of basal adenylate cyclase activity.
Figure 5b displays the results of two typical experiments in which either
PTH or ACSF was incubated at various pH’s. In these experiments, the agonists
were added directly to the cyclase assay, still dissolved in the pH-adjusted
ammonium acetate buffer. As expected from the prior experiment, there was
profound depression of adenylate cyclase stimulation at pH's 4 and below. At pH
values 6-9, there was moderate (35 -40 %) loss of bioactivity as compared to
controls. At a pH of 10, both bPTH and ACSF displayed apparent stimulation as
compared to that seen at the other pH points. With ACSF, pH 10 gave stimulation
above that shown by the control. Both of these curves are similar in shape to the
curve in Figure 5a.
Figure 5c also displays profiles of adenylate cyclase stimulation
generated by PTH or ACSF after exposure to various pH values. However, in these
experiments, the ammonium acetate was lyophilized and the sample was
resuspended in the usual vehicle (HAc/BSA) prior to assay. When treated in this
manner, there was little loss of activity for either PTH or ACSF as compared to
controls. Bioactivity at each pH value was over 90% of control activity with PTH.
ACSF bioactivity was greater than 95% at all except one of the pH points tested.
At a pH of 10 there was a loss of ACSF bioactivity.

CNBr Digest
ACSF was subjected to cyanogen bromide (CNBr) digestion in an attempt
to produce a peptide fragment that retained biological activity. PTH served as a
positive control. When bPTH was exposed to a 50-fold excess of CNBr (as
described in methods) all adenylate cyclase stimulating activity was destroyed.
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ACSF was incubated with both a 25 and 50-fold molar excess of CNBr. The
resulting digests had residual bioactivity, representing 11% and 13%,
respectively, of the undigested control bioactivity (in ng.eq.PTH/ml). In order to
ascertain whether this residual bioactivity was due to undigested ACSF or to an
active fragment, the digests were chromatographed using reverse phase HPLC as
described in the Methods section under "Source of ACSF".

When this was done,

the residual bioactivity eluted at 32% acetonitrile, the precise position in the
gradient at which ACSF,not exposed to CNBr, also elutes.

Lectin Experiments
In order to determine whether ACSF might be a glycoprotein and also to
evaluate the use of lectins as a purification strategy, the partially purified ACSF
was applied to both Concanavalin A and Wheat Germ lectin columns as described
in methods. 1>25l-labelled B-HCG was used as a positive control. As can be seen
in figure 6-a, this glycoprotein specifically binds to a concanavalin-A sepharose
column and is selectively eluted with good recovery from the column with amethyl-mannoside, the specific eluting agent. However, when ACSF was applied
to the columns in a similar fashion (figure 6b, 6c) bioactivity was recovered only
in the buffer eluted from the loading step.

There was no bioactivity in the

elution fractions and overall there was a very poor recovery of the total
bioactivity (<20% for concanavalin A, <10% for wheat germ lectin) applied to the
columns.

Figure 1

Renal adenylate cyclase stimulating activity given by
partially purified preparations of ACSF from a human breast
carcinoma and by bovinel-34 parathyroid hormone. Stimulation
of the assay is expressed by the ratio of 32P-cAMP generated by a
sample to 32P-cAMP generated by a basal or blank run. These
curves represent the aggregate dose-response curves averaged
over each individual assay performed.
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Figure 2
Results of a typical reduction experiment. Curves represent
the dose-response curves generated by dilutions of the reaction
mixtures described in Methods. Fig. 2a gives the results for
bPTH(1-34); Fig. 2b gives the results for ACSF. Symbols identify
curves representing either control PTH, control ACSF, or one of
the reducing conditions as described in Methods.
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Figure 3
Results of oxidation experiments with bPTH(1-34) and
ACSF. Curves represent the dose-response curves generated by
dilutions of the reaction mixtures described in methods. Each
curve represents either PTH or ACSF oxidized for a different
length of time. Figure 3c shows the loss of bioactivity of both
PTH and ACSF with progressively longer periods of oxidation.
Note the more gradual loss of bioactivity seen with ACSF.
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Figure 4
Results of an experiment in which ACSF was oxidized and
then subsequently reduced. As identified in the legend, curves
represent the dose-response curves generated by control ACSF,
ACSF oxidized for three hours in V\202, and ACSF oxidized for
three hours and subsequently reduced as before with BME, DTT, or
L-CYS.
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Figure 5
Results of pH experiments with bPTH (1-34) and ACSF.
- 5a displays the effects of lOOmM ammonium acetate at
different pH's on the renal cyclase assay.
- 5b represents the profile of bioactivity of PTH and ACSF over
various pH's. In these experiments the sample was added to the
cyclase assay dissolved in the pH-adjusted ammonium acetate.
Controls are equivalent amounts of ACSF or PTH assayed in the
standard fashion as described in Methods.
- 5c also represents the profile of bioactivity of PTH and ACSF
over various pH's. However, in these experiments the ammonium
acetate was lyophilized and the samples were resuspended in
5mM acetic acid / 0.5 mg/ml BSA immediately prior to assay.
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Figure 6

Results of Lectin experiments with ACSF.
- 6a. As described in Methods, 125l radiolabelled B -HCG was
used as a positive control for the Concanavalin A column. The
figure represents a profile of cpm recovered from the various
loading, washing, and eluting fractions applied to the column.
- 6b. This figure represents a profile of ACSF bioactivity
recovered from the various loading, washing, and eluting
fractions applied to the Concanavalin-A column.
- 6c. This figure displays the profile of ACSF bioactivity
recovered from the loading sample buffer, the two washes, and
the three elutions applied to the Wheat Germ Lectin column.
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Several laboratories are currently attempting to identify and to purify
the factor or factors responsible for HHM. The experiments described herein
were undertaken in pursuit of these goals. They were designed to investigate
how the adenylate cyclase-stimulating factor associated with HHM behaves when
it is exposed to a series of different physical and chemical conditions.

The

information gleaned from these experiments has been valuable in three respects.
First, it has helped to describe more fully the physical characteristics of the
factor(s).

Second, it has provided some valuable guidelines in constructing

purification schemes.

Finally, it has allowed comparison of the adenylate

cyclase stimulating activity and TGF activity, the two leading etiologic
contenders proposed to be responsible for HHM.
The partially purified ACSF used in these studies causes potent dosedependent stimulation of the renal cortical adenylate cyclase assay.

As

previously observed (120,125-128,137), the dose-response relationship is
essentially identical to that given by PTH. Since the averaged dose-response
curvies of ACSF and PTH so closely parallel each other, at least at the
concentrations tested, the two proteins probably stimulate the adenylate cyclase
system in an identical fashion. This fact lends further support to the notion that
the ACSF interacts directly with the PTH receptor.
The ACSA associated with HHM is not sensitive to chemical reduction. Lcysteine and DTT exert an adverse effect on the renal adenylate cyclase assay.
However, when these agents are diluted out so that they no longer affect the
assay, none of the three reducing agents employed diminishes the bioactivity of
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the ACSF. The concentrations of the three reducing agents employed, 300mM
BME, 130 mM L-cysteine, or 65mM DTT, represent severe reducing conditions.
Each of these conditions has been shown to be capable of dissociating disulfidelinked subunits of other purified and partially purified protein
(114,138,139).

hormones

Therefore, it can be stated with some certainty that disulfide

bonds are not crucial to the adenylate cyclase-stimulating activity associated
with HHM.
Lack of sensitivity to reducing agents stands at odds with the
descriptions of TGF activity reported by Mundy and his laboratory.

TGFs in

general are susceptible to reducing agents, and reports implicating TGFs as
pathogenetic factors in HHM have stressed susceptability to the reducing agent
DTT (114-118). This difference in behavior with respect to reducing conditions
demonstrates that the TGF and adenylate cyclase bioactivities associated with
HHM have different primary and tertiary structures.

These bioactivities may

reside in completely different peptides or they may reside in different regions of
the same molecule. Research currently underway in Dr. Stewart's laboratory
suggests that part of the adenylate cyclase stimulating protein not directly
associated with the ACSA may contain disulfide bonds. Preliminary SDS-PAGE
extraction studies indicate that under reducing conditions (50mM DTT), the
adenylate cyclase-stimulating factor(s) may dissociate into subunits, one which
contains the ACSA and one which does not (Stewart A, Burtis W, unpublished
observations).

It is interesting to speculate whether both bioactivities may

reside in the same molecule, the TGF activity dependent upon disulfide bonds, the
ACSA activity independent of such bonds.
In contrast to reduction, ACSA is sensitive to oxidation by hydrogen
peroxide.

Furthermore, this oxidation seems to be irreversible.

PTH is also
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sensitive to hydrogen peroxide as has previously been shown (139). However,
PTH has been shown to regain its bioactivity with subsequent reduction (139).
Under conditions of acidic pH, oxidation by hydrogen peroxide is fairly
specifically targeted to methionine residues (140,141). Although the pH of these
reactions was not controlled, the buffer containing the ACSF is a dilute acid
(5mM acetic acid). Hence, the oxidation reaction most likely altered methionine
residues. Other possible but less likely amino acid targets are cysteine, tyrosine
and tryptophan (141). The observed susceptibility to hydrogen peroxide suggests
that one of these four amino acids is important in maintaining the integrity of
the ACSF. The most likely of the four is methionine, but methionine oxidation
should be reversible upon subsequent reduction (141). It may be that there is
some impediment to refolding of the protein resulting from the manner in which
the reduction reactions were performed, or from features inherent in the primary
structure of the molecule. An alternative is that oxidation causes an ireversible
change in the protein, perhaps by altering one of the three amino acids other than
methionine, mentioned above.
It is interesting to compare the time courses of oxidation for PTH and
ACSF.

ACSF loses its bioactivity very gradually over several hours.

completely inactivated much more quickly, within thirty minutes.

PTH is
This

difference might be explained in one of two ways. First, ACSF may be a more
complexly folded protein with the oxidative targets partially protected within
the interior of the molecule. On the other hand, it may be that PTH is affected by
the rapid oxidation of methionine, while ACSF bioactivity is affected by the
slower oxidation of some other amino acid. Whatever the molecular basis for the
behavior of ACSF, it is clear that care should be taken to prevent oxidation during
the purification and handling of the peptide.
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In their attempts to further purify ACSF, Stewart and his associates have
employed ion-exchange chromatography.

However, using this method they

experienced substantial loses of bioactivity. Preliminary experiments suggested
that the ACSF might be unstable at the neutral pH’s involved in these studies. For
this reason, the activity of ACSF at different pH’s was examined in detail. It is
clear from these experiments that the buffer system used, 100 mM ammonium
acetate, exerts both a pH-dependent inhibition and stimulation of the renal
adneylate cyclase assay. There is profound suppression of cAMP formation at the
most acidic values and there is autonomous stimulation of cAMP production at
the most basic values.

In light of these effects, it is difficult to interpret the

experiments in which the sample was added to the assay dissolved in ammonium
acetate. It is impossible to tell whether the observed loss of bioactivity is due
to the ammonium acetate itself, or to a pH induced changed in the ACSF. If there
is such a change in the ACSF, it is a reversible one. In the set of experiments in
which the buffer is lyophilized before the sample is assayed, there is full
recovery of bioactivity. The only exception is at pH 10, where there is loss of
ACSF bioactivity. This loss of activity may be due to partial denaturation of the
protein (142) or perhaps to a conformational change secondary to the loss of
charge on a basic amino acid(s). In any case, it seems unlikely that the poor
recovery from ion exchange chromatography can be explained by any pHdependent, irreversible changes in the protein. The losses more likely were due
to irreversible binding of ACSF to the ion-exchange column.
ACSF was digested with cyanogen bromide in the hopes of producing a
peptide fragment that retained biological activity.

Such a fragment would be

more easily sequenced, and the sequence obtained would be of the biologically
active part of the molecule.

The digests did retain some activity in the
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adenylate cyclase assay, but HPLC analysis demonstrated that the activity
represented residual undigested ACSF. It is interesting that under the conditions
used in the experiments, PTH was completely digested while ACSF was not. This
mirrors the results of the oxidation experiments.

Since CNBr cleaves peptide

chains at methionine residues (143), these experiments again suggest that this
amino acid may be important to the protein's bioactivity and that it might be
located in a semi-protected domain in an interior portion of the molecule. These
CNBr experiments are but initial steps in the effort to generate an active
fragment.

It will be important to try more gentle CNBr conditions as well as

site-specific enzymatic reactions in an attempt to partially digest the protein.
Glycoproteins are ubiquitous in nature. Therefore, it is reasonable to
inquire whether the ACSF might be such a molecule. However, since the factor is
not yet purified to homogeneity, submitting it to the available chemical methods
for the detection of carbohydrate content would be of limited value.

If

carbohydrate were detected, it would not necessarily have been liberated from
the adenylate cyclase-stimulating protein.

Another way to approach this

problem is to attempt to specifically bind and elute the adenylate cyclasestimulating bioactivity to and from a lectin carbohydrate affinity column.
Lectins are proteins of nonimmune origin found in plants and microorganisms
that have the ability to noncovalently bind certain carbohydrate moieties (144).
Binding ACSF to such a column would both characterize it as a glycoprotein and
also offer a quick and simple purification step. With this goal in mind, partially
purified ACSF was applied to concanavalin A and wheat germ lectin, both
covlently attached to Sepharose beads. Conconvalin A recognizes a -mannose and
a -glucose residues; wheat germ lectin recognizes 8-N-acetyl glucosamine and a
-N-acetylneuraminic acid (144). As shown in the results section, it did not seem
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as if either of these lectins specifically bound the factor, suggesting that ACSF
does not contain any of the 4 sugar residues mentioned above in

accessible

locations. However, the low recovery of activity from these experiments makes
any interpretation perilous. Additional controls must be run to investigate the
possibilities that the ACSA bound nonspecifically to the Sepharose beads or that
the

columns

somehow destroyed the activity

(perhaps via protease

contamination). These experiments represent preliminary attempts and will be
expanded to include different lectins with different carbohydrate binding
specificities as well as the aforementioned controls.
With the experiments discussed above, the groundwork has been set to
complete the final purification of the adenylate cyclase-stimulating factor or
factors involved in HHM. This will allow a direct comparison of this protein to
the TGF activity also implicated in the syndrome.

With the recent finding of

Burtis and Stewart, that the protein appears to be composed of subunits, one
having ACSA and the other not having this activity, it is entirely possible that
both the TGF activity and the ACSA activities reside in the same molecule. This
hypothesis might also explain the disparity in the way in which the two
bioactivities respond to reducing conditions. Perhaps the TGF activity requires
the integrity of the disulfide bonds linking the two subunits together; the
adenylate cyclase stimulating activity apparently does not. Whether or not the
ACSF is eventually shown to possess TGF activity, it seems likely that its
significance will go beyond the realm of HHM. The work of Merendino £L

sL

(132) suggests that it plays a role in physiology as well as pathophysiology. The
question of its exact role in skin physiology warrants further investigation, a
task which will be much more easily accomplished once the protein is purified
and sequenced.
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